DrugPatentWatch Database Preview
Details for Patent: 9,155,716
Which drugs does patent 9,155,716 protect, and when does it expire?
Patent 9,155,716 protects LUMIGAN and is included in one NDA.
This patent has thirty-two patent family members in twenty-one countries.
This patent has thirty-two patent family members in twenty-one countries.
Summary for Patent: 9,155,716
| Title: | Enhanced bimatoprost ophthalmic solution |
| Abstract: | A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein. |
| Inventor(s): | Chang; Chin-Ming (Tustin, CA), Chang; James N. (Newport Beach, CA), Schiffman; Rhett M. (Laguna Beach, CA), Jordan; R. Scott (Trabuco Canyon, CA), Chang-Lin; Joan-En (Tustin, CA) |
| Assignee: | Allergan, Inc. (Irvine, CA) |
| Application Number: | 13/826,047 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 9,155,716
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | A METHOD OF LOWERING INTRAOCULAR PRESSURE | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 9,155,716
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,933,120 | Enhanced bimatoprost ophthalmic solution | ➤ Sign Up |
| 8,586,630 | Enhanced bimatoprost ophthalmic solution | ➤ Sign Up |
| 8,299,118 | Enhanced bimatoprost ophthalmic solution | ➤ Sign Up |
| 8,309,605 | Enhanced bimatoprost ophthalmic solution | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Family Members for US Patent 9,155,716
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 055050 | ➤ Sign Up | |||
| Austria | 431152 | ➤ Sign Up | |||
| Australia | 2006227757 | ➤ Sign Up | |||
| Brazil | PI0607447 | ➤ Sign Up | |||
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
